Fate Therapeutics (FATE)

• Market cap: $191M
• 1 day: 1.20%
• 5 days: -8.20%
• 1 month: -24.32%
• 3 months: -56.59%
• 6 months: -53.20%
• Year to date: -54.47%
• 1 year: -45.10%
• 5 years: -91.73%
• 10 years: -66.47%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Employees: 181

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

583% more call options, than puts

Call options by funds: $239K | Put options by funds: $35K

2% less capital invested

Capital invested by funds: $411M [Q2] → $401M (-$9.86M) [Q3]

9% less funds holding

Funds holding: 179 [Q2] → 163 (-16) [Q3]

9.43% less ownership

Funds ownership: 110.1% [Q2] → 100.67% (-9.43%) [Q3]

29% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 59

42% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 38